Statins are also metabolized by CYP3A4; therefore, high doses of lomitapide may suppress statin clearance by CYP3A4 and, as a result, expose the organism to serious side effects related to excessive statin exposure, such as myopathy and rhabdomyolysis. Here, CYP3A4 is linked to myopathy.